Weighing the balance: How analgesics used in chronic pain influence sleep?

British Journal of Pain

Volumn 8, Issue 3, 2014, Pages 107-118

  Bohra, Miqdad H ^a   Kaushik, Chhavi ^b   Temple, Daniel ^c   Chung, Sharon A ^a   Shapiro, Colin M ^d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b Mersey Deanery   (United Kingdom)

^c TEL AVIV UNIVERSITY   (Israel)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e Youthdale Child and Adolescent Sleep Clinic   (Canada)

Author keywords

Analgesia; Anticonvulsants; Antidepressants; Cannabinoids; Chronic pain; Non steroidal anti inflammatory drugs; Opiates; Pain management; Sleep; Sleep disorders

Indexed keywords

EID: 85006212932     PISSN: 20494637     EISSN: 20494645     Source Type: Journal    
DOI: 10.1177/2049463714525355     Document Type: Article

References (108)

1. Carskadon MA and Dement WC. Chapter 2. Normal human sleep: an overview. In: Kryger MH, Roth T and Dement WC (eds) Principles and practice of sleep medicine, 5th edn. St Louis: Elsevier Saunders, 2011, pp. 16–26.
2. Carli G, Montesano A, Rapezzi S, et al. Differential effects of persistent nociceptive stimulation on sleep stages. Behav Brain Res 1987; 26(2–3): 89–98.
3. Kontinen VK, Ahnaou A, Drinkenburg WHIM, et al. Sleep and EEG patterns in the chronic constriction injury model of neuropathic pain. Physiol Behav 2003; 78(2): 241–246.
4. Monassi CR, Bandler R and Keay KA. A subpopulation of rats shows social and sleep-waking changes typical of chronic neuropathic pain following peripheral nerve injury. Eur J Neurosci 2003; 17(9): 1907–1920.
5. Lavigne G, Zucconi M, Castronovo C, et al. Sleep arousal response to experimental thermal stimulation during sleep in human subjects free of pain and sleep problems. Pain 2000; 84(2–3): 283–290.
6. Drewes AM, Svendsen L, Taagholt SJ, et al. Sleep in rheumatoid arthritis: a comparison with healthy subjects and studies of sleep/wake interactions. Br J Rheumatol 1998; 37(1): 71–81.
7. Roehrs T, Diederichs C, Gillis M, et al. Nocturnal sleep, daytime sleepiness and fatigue in fibromyalgia patients compared to rheumatoid arthritis patients and health controls: a preliminary study. Sleep Med 2013; 14(1): 109–115.
8. Morin CM, Gibson D and Wade J. Self-reported sleep and mood disturbance in chronic pain patients. Clin J Pain 1998; 14(4): 311–314.
9. Hicks RA, Coleman DD, Ferrante F, et al. Pain thresholds in rats during recovery from REM sleep deprivation. Percept Mot Skills 1979; 48(3): 687–690.
10. Hakki Onen S, Alloui A, Jourdan D, et al. Effects of rapid eye movement (REM) sleep deprivation on pain sensitivity in the rat. Brain Res 2001; 900(2): 261–267.
11. Ukponmwan OE, Rupreht J and Dzolijic MR. REM sleep deprivation decreases the antinociceptive property of enkephalinase-inhibition, morphine and coldwater-swim. Gen Pharmacol 1984; 15(3): 255–258.
12. Moldofsky H and Scarisbrick P. Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom Med 1976; 38(1): 35–44.
13. Onen SH, Alloui A, Gross A, et al. The effects of total sleep deprivation, selective sleep interruption and sleep recovery on pain tolerance thresholds in healthy subjects. J Sleep Res 2001; 10(1): 35–42.
14. Lentz MJ, Landis CA, Rothermel J, et al. Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. J Rheumatology 1999; 26(7): 1586–1592.
15. Roehrs T, Hyde M, Blaisdell B, et al. Sleep loss and REM sleep loss are hyperalgesic. Sleep 2006; 29(2): 145–151.
16. Baghdoyan HA. Hyperalgesia induced by REM sleep loss: a phenomenon in search of a mechanism. Sleep 2006; 29(2): 137–139.
17. Tiede W, Magerl W, Baumgärtner U, et al. Sleep restriction attenuates amplitudes and attentional modulation of pain-related evoked potentials, but augments pain ratings in healthy volunteers. Pain 2010; 148(1): 36–42.
18. Campbell CM, Bounds SC, Simango MB, et al. Selfreported sleep duration associated with distraction analgesia, hyperemia, and secondary hyperalgesia in the heat-capsaicin nociceptive model. Eur J Pain 2011; 15(6): 561–567.
19. Bigatti SM, Hernandez AM, Cronan TA, et al. Sleep disturbances in fibromyalgia syndrome: relationship to pain and depression. Arthritis Rheumatol 2008; 59(7): 961–967.
20. Haack M, Sanchez E and Mullington JM. Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers. Sleep 2007; 30(9): 1145–1152.
21. Consoli G, Marazziti D, Ciapparelli A, et al. The impact of mood, anxiety, and sleep disorders on fibromyalgia. Compr Psychiatry 2012; 53(7): 962–967.
22. Schweitzer PK. Chapter 46. Drugs that affect sleep and wakefulness. In: Kryger MH, Roth T and Dement WC (eds) Principles and practice of sleep medicine, 5th edn. St Louis: Elsevier Saunders, 2011, pp. 542–560.
23. Mayers AG and Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005; 20(8): 533–559.
24. Hartmann E and Cravens J. The effects of long term administration of psychotropic drugs on human sleep: III. The effects of amitriptyline. Psychopharmacologia 1973; 33(2): 185–202.
25. Wilson S and Argyropoulos S. Antidepressants and sleep. Drugs 2006; 65(7): 927–947.
26. Hauser W, Bernardy K, Uceyler N, et al. Treatment of fibromyalgia syndrome with antidepressants: a metaanalysis. JAMA 2009; 301(2): 198–209.
27. Wichniak A, Wierzbicka A and Jernajczyk W. Sleep and antidepressant treatment. Curr Pharm Des 2012; 18(36): 5802–5817.
28. Damasceno F, Skinner GO, Gomes A, et al. Systemic amitriptyline administration does not prevent the increased thermal response induced by paradoxical sleep deprivation. Pharmacol Biochem Behav 2009; 94: 51–55.
29. Hoque R and Chesson AL Jr. Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/ REM sleep without atonia: literature review, qualitative scoring, and comparative analysis. J Clin Sleep Med 2010; 6(1): 79–83.
30. Kim SW, Shin IS, Kim JM, et al. Bupropion may improve restless legs syndrome: a report of three cases. Clin Neuropharmacol 2005; 28(6): 298–301.
31. Bayard M, Bailey B, Acharya D, et al. Bupropion and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med 2011; 24(4): 422–428.
32. Edwards RR, Quartana PJ, Allen RP, et al. Alterations in pain processing in treated and untreated patients with restless legs syndrome: associations with sleep disruption. J Pain 2011; 12(6): 603–609.
33. Lee JJ, Erdos J, Wilkosz MF, et al. Bupropion as a possible treatment option for restless legs syndrome. Ann Pharmacother 2009; 43(2): 370–374.
34. Perrott J, Renda F, Fitzgerald H, et al. Effects of amitriptyline on AHI (abstract). Sleep 2009 (supplement); 32: A42.
35. Moldofsky H. Rheumatic manifestations of sleep disorders. Current Opinion in Rheumatology 2010, 22(1): 59-63.
36. Smith MT, Wickwire EM, Grace EG, et al. Sleep disorders and their association with laboratory pain sensitivity in temporomandibular joint disorder. Sleep 2009; 32(6): 779–790.
37. Sanders AE, Essick GK, Fillingim R, et al. Sleep apnea symptoms and risk of temporomandibular disorder: OPPERA cohort. J Dent Res 2013; 92(7): S70–S77.
38. Inturrisie CE. Clinical pharmacology of opioids for pain. Clin J Pain 2002; 18(4 Suppl.): S3–S13.
39. Gana TJ, Pascual MLG, Fleming RRB, et al. Extendedrelease tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo controlled clinical trial. Curr Med Res Opin 2006; 22(7): 1391–1401.
40. Turk DC and Cohen MJM. Sleep as a marker in the effective management of chronic osteoarthritis pain with opioid analgesics. Semin Arthritis Rheum 2010; 39(6): 477–490.
41. Kay DC, Pickworth WB and Neider GL. Morphinelike insomnia from heroin in nondependent human addicts. Br J Clin Pharmacol 1981; 11(2): 159–169.
42. Staedt J, Wassmuth F, Stoppe G, et al. Effects of chronic treatment with methadone and naltrexone on sleep in addicts. Eur Arch Psychiatry Clin Neurosci 1996; 246(6): 305–309.
43. Shaw IR, Lavigne G, Mayer P, et al. Acute intravenous administration of morphine perturbs sleep architecture in healthy pain-free young adults: a preliminary study. Sleep 2005; 28(6): 677–682.
44. Dimsdale JE, Norman D, DeJardin D, et al. The effect of opioids on sleep architecture. J Clin Sleep Med 2007; 3(1): 33–36.
45. Walker JM and Farney RJ. Are opioids associated with sleep apnea? A review of the evidence. Curr Pain Headache Rep 2009; 13(2): 120–126.
46. Mogri M, Khan MI, Grant BJ, et al. Central sleep apnea induced by acute ingestion of opioids. Chest 2008; 133(6): 1484–1488.
47. Walker JM, Farney RJ, Rhondeau SM, et al. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 2007; 3(5): 455–461.
48. Farney RJ, Walker JM, Cloward V, et al. Sleep-disordered breathing associated with long-term opioid therapy. Chest 2003; 123(2): 632–639.
49. Sharkey KM, Kurth ME, Anderson BJ, et al. Obstructive sleep apnea is more common than central sleep apnea in methadone maintenance therapy patientswith subjective sleep complaints. Drug Alcohol Depend 2010; 108(1–2): 77–83.
50. Webster LR, Choi Y, Desai H, et al. Sleep disordered breathing and chronic opioid therapy. Pain Med 2008; 9(4): 425–432.
51. Moore JT and Kelz MB. Opiates, sleep, and pain: the adenosinergic link. Anesthesiology 2009; 111(6): 1175–1176.
52. Lee M, Silverman S, Hansen H, et al. A comprehensive review of opioid induced hyperalgesia. Pain Physician 2011; 14: 145–161.
53. Steinmiller CL, Roehrs TA, Harris E, et al. Differential effect of codeine on thermal nociceptive sensitivity in sleepy versus non sleepy healthy subjects. Exp Clin Psychopharmacol 2010; 18(3): 277–283.
54. Dash MB, Douglas CL, Vyazovskiy VV, et al. Long term homeostasis of extracellular glutamate in the rat cerebral cortex across sleep and waking states. J Neurosci 2009; 29(3): 620–629.
55. Woo H and Mason P. Brainstem modulation of pain during sleep and waking. Sleep Med Rev 2003; 7(2): 145–154.
56. Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009; Jul 8;(3):CD007076. doi: 10.1002/14651858.CD007076.pub2.
57. Brick N. Carbamazepine for acute and chronic pain in adults. Clin J Oncol Nurs 2011; 15(3): 335–336.
58. Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011, Mar 16;(3):CD007938. doi: 10.1002/14651858. CD007938.pub2.
59. Dickenson AH, Mathews EA and Suzuki R. Neurobiology of neuropathic pain: mode of action of anticonvulsants. Eur J Pain 2002; 6(Suppl. A): 51–60.
60. Drake ME Jr, Pakalnis A, Bogner JE, et al. Outpatient sleep recording during antiepileptic drug monotherapy. Clin Electroencephalogr 1990; 21: 170–173.
61. Legros B and Bazil CW. Effects of antiepileptic drugson sleep architecture: a pilot study. Sleep Med 2003; 4: 51–55.
62. Gigli GL, Baldinetti F, Placidi F, et al. Nocturnal sleep and daytime somnolence in untreated patients with temporal lobe epilepsy: change after treatment with controlled-release carbamazepine. Epilepsia 1997; 38: 696–701.
63. Placidi F, Diomedi M, Scalise A, et al. Effect of anticonvulsants on nocturnal sleep in epilepsy. Neurology 2000; 54(Suppl. 1): S25–S32.
64. Sammaritano M and Sherwin A. Effect of anticonvulsant on sleep. Neurology 2000; 54(Suppl. 1): S16–S24.
65. Cho YW, Kim DH and Motamedi GK. The effect of levetiracetam monotherapy on subjective sleep quality and objective sleep parameters in patients with epilepsy: compared with the effect of carbamazepine-CR monotherapy. Seizure 2011; 20(4): 336–339.
66. Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel. J Biol Chem 1996; 271(10): 5768–5776.
67. Wang M, Offord J, Oxender DL, et al. Structural requirement of the calcium-channel subunit alpha2delta for gabapentin bindings. Biochem J 1999; 342: 313–320.
68. Roth T, van Seventer R and Murphy TK. The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials. Curr Med Res Opin 2010; 26(10): 2411–2419.
69. Kim JS, Bashford G, Murphy TK, et al. Safety and efficacy of pregabalin in patients with central poststroke pain. Pain 2011; 152(5): 1018–1023.
70. Straube S, Derry S, Moore RA, et al. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology 2010; 49(4): 706–715.
71. Russell IJ, Crofford LJ, Leon T, et al. The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Med 2009; 10(6): 604–610.
72. Kubota T, Fang J, Meltzer LT, et al. Pregabalin enhances non-rapid eye movement sleep. J Pharmacol Exp Ther 2001; 299(3): 1095–1105.
73. De Haas S, Otte A, de Weerd A, et al. Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy. J Clin Sleep Med 2007; 3(5): 473–478.
74. Hindmarch I, Dawson J and Stanley N. A doubleblind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005; 28(2): 187–193.
75. Buvanendran A, Kroin JS, Della Valle CJ, et al. Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial. Anesth Analg 2010; 110: 199–207.
76. Placidi F, Mattia D, Romigi A, et al. Gabapentininduced modulation of interictal epileptiform activity related to different vigilance levels. Clin Neurophysiol 2000; 111: 1637–1642.
77. Rao ML, Clarenbach P, Vahlensieck M, et al. Gabapentin augments whole blood serotonin in healthy young men. J Neural Transm 1988; 73: 129–134.
78. Foldvary-Schaefer N, Sanchez IDL, Karafa M, et al. Gabapentin increases slow wave sleep in normal adults. Epilepsia 2002; 43: 1493–1497.
79. Häuser W, Bernardy K, Uçeyler N, et al. Treatment of fibromyalgia syndrome with gabapentin and pregabalin – a meta-analysis of randomized controlled trials. Pain 2009; 145(1–2): 69–81.
80. Guindon J and Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 2009; 8: 403–421.
81. Hohmann AG and Suplita RL. Endocannabinoid mechanisms of pain modulation. AAPS J 2006; 8(4): E693–E708 (article 79).
82. Lynch ME and Campbell F. Cannabinoids for treatment of chronic non-cancer pain: a systematic review of randomized trials. Br J Clin Pharmacol 2011; 72(5): 735–744.
83. Martin-Sanchez E, Furukawa TA, Taylor J, et al. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med 2009; 10: 1353–1368.
84. Pivik RT, Zarcone V, Dement WC, et al. Delta-9-tetrahydrocannabinol and synhexl: effects on human sleep patterns. Clin Pharmacol Ther 1972; 13: 426–435.
85. Feinberg I, Jones R, Walker JM, et al. Effects of high dosage delta-9-tetrahydrocannabinol on sleep patterns in man. Clin Pharmacol Ther 1975; 17: 458–466.
86. Freemon FR. The effect of chronically administered delta-9-tetrahydrocannabinol upon the polygraphically monitored sleep of normal volunteers. Drug Alcohol Depend 1982; 10: 345–353.
87. Arias-Carrión O, Huitrón-Reséndiz S, Arankowsky-Sandoval G, et al. Biochemical modulation of the sleep-wake cycle: endogenous sleep-inducing factors. J Neurosci Res 2011; 89(8): 1143–1149.
88. Murillo-Rodríguez E, Poot-Ake A, Arias-Carrió NO, et al. The emerging role of the endocannabinoid system in the sleep-wake cycle modulation. Cent Nerv Syst Agents Med Chem 2011; 11(3): 189–196.
89. Ware MA, Fitzcharles MA, Joseph L, et al. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010; 110(2): 604–610.
90. Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, et al. The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent. Behav Neurosci 2008; 122(6): 1378–1382.
91. Nicholson AN, Turner C, Stone BM, et al. Effect of delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol 2004; 24(3): 305–313.
92. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010; 182(14): 694–701.
93. Nurmikko TJ, Serpell MG, Hoggart B, et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebocontrolled clinical trial. Pain 2007; 133(1–3): 210–220.
94. McCarberg BH. Cannabinoids: their role in pain and palliation. J Pain Palliat Care Pharmacother 2007; 21(3): 19–28.
95. Roberts JD, Gennings C and Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 2006; 530(1–2): 54–58.
96. Carley DW, Pavlovic S, Janelidze M, et al. Functional role for cannabinoids in respiratory stability during sleep. Sleep 2002; 25(4): 388–395.
97. Dempsey J. ‘Functional Role for Cannabinoids in Respiratory Stability During Sleep’ by D.W. Carley, et al, Sleep 2002; 25(4): 396–397.
98. Bolla KI, Lesage SR, Gamaldo CE, et al. Sleep disturbance in heavy marijuana users. Sleep 2008; 31(6): 901–908.
99. Bolla KI, Lesage SR, Gamaldo CE, et al. Polysomnogram changes in marijuana users who report sleep disturbances during prior abstinence. Sleep Med 2010; 11(9): 882–889.
100. Vorspan F, Guillem E, Bloch V, et al. Cannabis withdrawal syndrome in patients with cannabis dependence only, and in patients with cannabis and opioid dependence. Encéphale 2011; 37(4): 266–272.
101. Hayaishi O. Molecular mechanisms of sleep-wake regulation: roles of prostaglandins D2 and E2. FASEB J 1991; 5: 2575–2581.
102. Muprhy PJ, Badia P, Myers BL, et al. Non-steroidal drugs affect normal sleep pattern in humans. Physiol Behav 1994; 55(6): 1063–1066.
103. Murphy PJ, Myers BL and Badia P. Nonsteroidal anti-inflammatory drugs alter body temperature and suppress melatonin in humans. Physiol Behav 1996; 59(1): 133–139.
104. Bernheim HA. Is prostaglandin E2 involved in the pathogenesis of fever? Effects of interleukin-1 on the release of prostaglandins. Yale J Biol Med 1986; 59(2): 151–158.
105. Gengo F. Effects of ibuprofen on sleep quality as measured using polysomnography and subjective measures in healthy adults. Clin Ther 2006; 28(11): 1820–1826.
106. Lavie P, Nahir M, Lorber M, et al. Non-steroidal anti-inflammatory drug therapy in rheumatoid arthritis patients. Lack of association between clinical improvement and effects on sleep. Arthritis Rheumatol 1991; 34(6): 655–659.
107. Iacovides S, Avidon I, Bentley A, et al. Diclofenac potassium restores objective and subjective measures of sleep quality in women with primary dysmenorrhea. Sleep 2009; 32(8): 1019–1026.
108. Burgess KR, Fan JL, Peebles K, et al. Exacerbation of obstructive sleep apnea by oral indomethacin. Chest 2010; 137(3): 707–710.